First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail pr
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1 The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2
The first surgical procedures using the CATALYSTEM Primary Hip System were completed last week in the United States by three prominent orthopaedic surgeons who commented on their experience utilizing the system for the first time.
“Smith+Nephew's new CATALYSTEM Primary Hip System with RI.HIP NAVIGATION represents the beginning of a new era combining advanced technology and patient personalization that will, without doubt, enhance patient outcomes,” said Dr. Thorsten Seyler of Duke University.
The CATALYSTEM Primary Hip System also utilizes proprietary, patent-pending, ACCUBROACH◊ Technology delivering proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating.3,4
“The instruments were exceptionally user-friendly and ideal for the direct anterior approach,” commented George Haidukewych MD, Orlando Health, Orlando, Florida. “The broaches showed a significant improvement in performance, offering superior cutting and a more precise feel for rotational stability. In comparison to other implants I've used in recent years, these stand out as markedly better. Overall A-plus…it could not have gone better.”
Dr. Ran Schwarzkopf, Orthopedic Adult Hip and Knee Reconstruction Surgeon at NYU Langone Health commented, "The case went smoothly and exceeded all my expectations. It's the best anatomically fitting stem I've ever seen - it fit the patient's anatomy perfectly. The advantage of the broaches giving exact stem-to-broach positioning is unmatched in the industry.”
To learn more about Smith+Nephew's new CATALYSTEM Primary Hip System for total hip arthroplasty, please visit https://www.smith-nephew.com/en/health-care-professionals/products/orthopaedics/catalystem
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- Smith + Nephew 2024. Finite Element Analysis of the CATALYSTEM Hip Stem Design. Internal Report. OR-24-025
- Smith + Nephew 2024. Surgeon Feedback on the CATALYSTEM Total Hip System. Internal Report. CSD.REC.24.001
- Smith + Nephew 2024. Cadaveric study of the repeatability of CATALYSTEM broach and femoral stem seating level. Internal Report. 10144794
- Smith + Nephew 2024. CATALYSTEM Accubroach Femur to Bone Interaction Design Rationale. Internal Report. 10142827
This document is provided for informational purposes and is not intended to serve as medical advice. It is the responsibility of healthcare professionals to determine and utilise the appropriate products and techniques according to their own clinical judgment for each of their patients.
The surgeon testimonials set out in this document represent the individual surgeon's opinions, findings, beliefs, and/or experiences. Individual results will vary. The surgeons featured were involved in the development of CATALYSTEM and were compensated by Smith+Nephew for their time.
To review the information needed to understand and use CATALYSTEM safely and effectively, including indications for use, contraindications, effects, precautions, and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.
Products featured may not be available in individual markets due to regulatory and/or medical practices. Please contact your Smith+Nephew representative if you have questions about availability of Smith+Nephew products in your area.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
- 祁门决赛揭晓!寻找“小城更新浪潮”中的新解法
- 《家有儿女之神犬当家》上映 全国寒假营观影活动同步启动
- 医生,搞错了吧,我才30多岁,怎么会得这个“老年病”?——福州爱尔眼科
- General Fusion Partners with Canadian Nuclear Laboratories to Advance Commercial Power Plant Design
- 怡和嘉业:以科技之光照亮公益之路
- 重磅发布:《跟着课本去旅行》走进皇城相府,媒体赋能研学之旅
- 泰雷兹引领毛里求斯国民身份识别系统的创新数字化转型
- 法律法规数据库优选Alpha法律系统,领跑国内法律数据库行业
- 西部数据携全新解决方案亮相FMS2024,推动释放人工智能创新力量
- nCino to Participate in Upcoming Investor Event
- 搭建上门预约平台,选择软件开发公司需谨慎,
- IBM发布2024年大中华区战略:聚焦企业级AI,发力汽车行业,拓展伙伴生态
- 驰援洪水灾区 长虹美菱推进ESG建设
- 张亮麻辣烫扬帆出海,遍及4大洲15国!
- 平凡一天完美收官 寻找美食“小确幸”
- 夏日咖茶香 Lavazza两款定制新品全国上市
- Ras Al-Khair经济特区通过海事行业的国际合作伙伴关系和海上集群吸引投资
- 金矢留学对话南安普顿大学:排名持续提升,毕业生备受雇主青睐
- 横琴大动作——亲子旅游圣地 横琴梧桐树主题乐园盛大试营业
- 体验美食便捷之选 外卖满足多样需求
- 瑞派亮相国际亚洲兽医大会暨展览会 汇聚业界精英嘉宾鼎盛阵容,联结全球宠物行业精英人脉!
- 《惜花芷》热播掀热潮,田淼张婧仪母女情深引热议
- 2024盛世东方国潮大赛——5.26新闻发布会圆满落幕
- instagram协议群发推广引流助手,ins自动引流神器
- LMN 2024世界激光制造大会于大族激光盛大启幕,共探激光技术新趋势
- 中信银行西安分行“守护群众钱袋子”,切实筑牢金融安全防线
- 盈透证券新增芝加哥期权交易所欧洲衍生品(CEDX)交易
- “退役军人医疗救助”项目捐赠暨“2024退役军人家庭-全年医疗费用保险卡”升级上线启动仪式在京举行
- NetJets宣布与著名艺术家Silvère Jarrosson合作
- 浩鼎启动OBI-992一/二期临床试验
推荐
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯